NCT04453137 - Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

567

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

November 16, 2021

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL

Adalimumab originator

Subcutaneous injection every other week

BIOLOGICAL

Adalimumab biosimilar

Subcutaneous injection every other week

Trial Locations (25)

Unknown

9901, Tbilisi

Alvotech Swiss AG - 9904, Tbilisi

Alvotech Swiss AG - Site 9902, Tbilisi

Alvotech Swiss AG - Site 9903, Tbilisi

Alvotech Swiss AG - Site 3501, Reykjavik

Alvotech Swiss AG - Site 4803, Gdansk

Alvotech Swiss AG - Site 4804, Krakow

Alvotech Swiss AG - Site 4807, Krakow

Alvotech Swiss AG - Site 4805, Lodz

Alvotech Swiss AG - Site 4806, Torun

Alvotech Swiss AG - 4808, Wroclaw

Alvotech Swiss AG - Site 7001, Kemerovo

Alvotech Swiss AG - Site 7005, Krasnodar

Alvotech Swiss AG - Site 7003, Saint Petersburg

Alvotech Swiss AG - Site 7004, Saint Petersburg

Alvotech Swiss AG - Site 7006, Saint Petersburg

Alvotech Swiss AG - Site 7002, Saratov

Alvotech Swiss AG - Site 3805, Kharkiv

Alvotech Swiss AG - Site 3807, Kharkiv

Alvotech Swiss AG - Site 3801, Kyiv

Alvotech Swiss AG - Site 3806, Kyiv

Alvotech Swiss Ag - Site 3802, Rivne

Alvotech Swiss AG - Site 3804, Uzhhorod

Alvotech Swiss AG - Site 3803, Zaporizhzhya

51-685

Wromedica Centrum Zdrowia, Wroclaw

All Listed Sponsors

lead

Alvotech Swiss AG

INDUSTRY